160 related articles for article (PubMed ID: 34015010)
1. PIVKA-II: A biomarker for diagnosing and monitoring patients with pancreatic adenocarcinoma.
Tartaglione S; Mancini P; Viggiani V; Chirletti P; Angeloni A; Anastasi E
PLoS One; 2021; 16(5):e0251656. PubMed ID: 34015010
[TBL] [Abstract][Full Text] [Related]
2. Protein Induced by Vitamin K Absence II (PIVKA-II) as a potential serological biomarker in pancreatic cancer: a pilot study.
Tartaglione S; Pecorella I; Zarrillo SR; Granato T; Viggiani V; Manganaro L; Marchese C; Angeloni A; Anastasi E
Biochem Med (Zagreb); 2019 Jun; 29(2):020707. PubMed ID: 31223261
[TBL] [Abstract][Full Text] [Related]
3. Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion.
Poté N; Cauchy F; Albuquerque M; Voitot H; Belghiti J; Castera L; Puy H; Bedossa P; Paradis V
J Hepatol; 2015 Apr; 62(4):848-54. PubMed ID: 25450201
[TBL] [Abstract][Full Text] [Related]
4. Protein Induced by Vitamin K Absence II: A Potential Biomarker to Differentiate Pancreatic Ductal Adenocarcinoma from Pancreatic Benign Lesions and Predict Vascular Invasion.
Yang Y; Li G; Zhang Y; Cui Y; Liu J
J Clin Med; 2023 Apr; 12(8):. PubMed ID: 37109105
[TBL] [Abstract][Full Text] [Related]
5. Protein induced by vitamin K absence or antagonist-II (PIVKA-II) specifically increased in Italian hepatocellular carcinoma patients.
Viggiani V; Palombi S; Gennarini G; D'Ettorre G; De Vito C; Angeloni A; Frati L; Anastasi E
Scand J Gastroenterol; 2016 Oct; 51(10):1257-62. PubMed ID: 27227515
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP.
Choi JY; Jung SW; Kim HY; Kim M; Kim Y; Kim DG; Oh EJ
World J Gastroenterol; 2013 Jan; 19(3):339-46. PubMed ID: 23372355
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinoma.
Park SJ; Jang JY; Jeong SW; Cho YK; Lee SH; Kim SG; Cha SW; Kim YS; Cho YD; Kim HS; Kim BS; Park S; Bang HI
Medicine (Baltimore); 2017 Mar; 96(11):e5811. PubMed ID: 28296720
[TBL] [Abstract][Full Text] [Related]
8. PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma.
Feng H; Li B; Li Z; Wei Q; Ren L
BMC Cancer; 2021 Apr; 21(1):401. PubMed ID: 33849479
[TBL] [Abstract][Full Text] [Related]
9. Performance evaluation of serum PIVKA-II measurement using HISCL-5000 and a method comparison of HISCL-5000, LUMIPULSE G1200, and ARCHITECT i2000.
Ryu MR; Kang ES; Park HD
J Clin Lab Anal; 2019 Jul; 33(6):e22921. PubMed ID: 31131509
[TBL] [Abstract][Full Text] [Related]
10. PANC-1 Cell Line as an Experimental Model for Characterizing PIVKA-II Production, Distribution, and Molecular Mechanisms Leading to Protein Release in PDAC.
Farina A; Tartaglione S; Preziosi A; Mancini P; Angeloni A; Anastasi E
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542466
[TBL] [Abstract][Full Text] [Related]
11. Serum des-gamma-carboxyprothrombin in patients with pancreatic head adenocarcinoma.
Kemik AS; Kemik O; Purisa S; Tuzun S
Bratisl Lek Listy; 2011; 112(10):552-4. PubMed ID: 21954538
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of PIVKA-II in the detection of hepatocellular carcinoma based on real-world clinical data.
Yu R; Tan Z; Xiang X; Dan Y; Deng G
BMC Cancer; 2017 Sep; 17(1):608. PubMed ID: 28863782
[TBL] [Abstract][Full Text] [Related]
13. Modeling the time-related fluctuations of AFP and PIVKA-II serum levels in patients with cirrhosis undergoing surveillance for hepatocellular carcinoma.
Ricco G; Cosma C; Bedogni G; Biasiolo A; Guarino M; Pontisso P; Morisco F; Oliveri F; Cavallone D; Bonino F; Plebani M; Brunetto MR
Cancer Biomark; 2020; 29(2):189-196. PubMed ID: 32623383
[TBL] [Abstract][Full Text] [Related]
14. Comparing prothrombin induced by vitamin K absence-II (PIVKA-II) with the oncofetal proteins glypican-3, Alpha feto protein and carcinoembryonic antigen in diagnosing hepatocellular carcinoma among Egyptian patients.
Abd El Gawad IA; Mossallam GI; Radwan NH; Elzawahry HM; Elhifnawy NM
J Egypt Natl Canc Inst; 2014 Jun; 26(2):79-85. PubMed ID: 24841158
[TBL] [Abstract][Full Text] [Related]
15. Vitamin K deficiency in critical ill patients; a prospective observational study.
Dahlberg S; Schurgers L; Schött U; Kander T
J Crit Care; 2019 Feb; 49():105-109. PubMed ID: 30415179
[TBL] [Abstract][Full Text] [Related]
16. The combination of PIVKA-II and AFP improves the detection accuracy for HCC in HBV caucasian cirrhotics on long-term oral therapy.
Loglio A; Iavarone M; Facchetti F; Di Paolo D; Perbellini R; Lunghi G; Ceriotti F; Galli C; Sandri MT; Viganò M; Sangiovanni A; Colombo M; Lampertico P
Liver Int; 2020 Aug; 40(8):1987-1996. PubMed ID: 32301212
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic value of serum PIVKA-II levels for BCLC early hepatocellular carcinoma and correlation with HBV DNA.
Wu J; Xiang Z; Bai L; He L; Tan L; Hu M; Ren Y
Cancer Biomark; 2018; 23(2):235-242. PubMed ID: 30103302
[TBL] [Abstract][Full Text] [Related]
18. PIVKA-II as a Potential New Biomarker for Hepatocellular Carcinoma - A Pilot Study.
Svobodova S; Karlikova M; Topolcan O; Pecen L; Pestova M; Kott O; Treska V; Slouka D; Kucera R
In Vivo; 2018; 32(6):1551-1554. PubMed ID: 30348715
[TBL] [Abstract][Full Text] [Related]
19. Measurement of des-gamma-carboxy prothrombin levels in hemodialysis patients positive for anti-hepatitis virus C antibody.
Kato A; Yasuda H; Togawa A; Yamamoto T; Yonemura K; Maruyama T; Maruyama Y; Hishida A
Clin Nephrol; 2002 Oct; 58(4):296-300. PubMed ID: 12400845
[TBL] [Abstract][Full Text] [Related]
20. Development and evaluation of analytical performance of a fully automated chemiluminescent immunoassay for protein induced by vitamin K absence or antagonist II.
Fujita K; Kinukawa H; Ohno K; Ito Y; Saegusa H; Yoshimura T
Clin Biochem; 2015 Dec; 48(18):1330-6. PubMed ID: 26210849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
